Johnson & Johnson (NYSE:JNJ) Stake Reduced by Boston Family Office LLC

Boston Family Office LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 1.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 86,961 shares of the company’s stock after selling 1,446 shares during the quarter. Boston Family Office LLC’s holdings in Johnson & Johnson were worth $12,576,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. boosted its position in Johnson & Johnson by 10.5% during the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after acquiring an additional 329,473 shares during the period. United Bank grew its position in Johnson & Johnson by 5.6% in the 3rd quarter. United Bank now owns 3,788 shares of the company’s stock valued at $614,000 after buying an additional 202 shares in the last quarter. Benjamin Edwards Inc. increased its stake in Johnson & Johnson by 5,447.8% during the 3rd quarter. Benjamin Edwards Inc. now owns 121,996 shares of the company’s stock valued at $19,773,000 after buying an additional 119,797 shares during the period. Ascent Group LLC raised its position in shares of Johnson & Johnson by 80.2% during the 3rd quarter. Ascent Group LLC now owns 34,026 shares of the company’s stock worth $5,514,000 after buying an additional 15,141 shares in the last quarter. Finally, Concentric Capital Strategies LP lifted its stake in shares of Johnson & Johnson by 66.5% in the 3rd quarter. Concentric Capital Strategies LP now owns 10,058 shares of the company’s stock worth $1,630,000 after acquiring an additional 4,016 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Leerink Partners dropped their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Bank of America raised their target price on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday, March 5th. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Finally, Barclays lifted their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $165.89 on Tuesday. The stock’s fifty day simple moving average is $159.06 and its 200-day simple moving average is $156.07. The company has a market capitalization of $399.76 billion, a price-to-earnings ratio of 24.95, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.